See more : Atlantic Coastal Acquisition Corp. II (ACAB) Income Statement Analysis – Financial Results
Complete financial analysis of BioNxt Solutions Inc. (XPHYF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioNxt Solutions Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- AccuStem Sciences Limited (ACMSY) Income Statement Analysis – Financial Results
- Allied Farmers Limited (ALF.NZ) Income Statement Analysis – Financial Results
- Metalex Ventures Ltd. (MXTLF) Income Statement Analysis – Financial Results
- Kering SA (PPX.DE) Income Statement Analysis – Financial Results
- U and I Group PLC (UAI.L) Income Statement Analysis – Financial Results
BioNxt Solutions Inc. (XPHYF)
About BioNxt Solutions Inc.
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
BioNxt Solutions Announces Change of Directors
XPhyto Therapeutics says director and founder Professor Dr Raimar Loebenberg receives leadership award from Canadian Society for Pharmaceutical Science
XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head
XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year
XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds
XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions
XPhyto Therapeutics realizing 'significant synergies' after integration of 3a-diagnostics GmbH
XPhyto Therapeutics announces appointment of Drahoslav Zdarek as the company's head of sales, Europe
Source: https://incomestatements.info
Category: Stock Reports